SELECT PUBLICATIONS

Fan C et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006;355(6):560-9. Abstract

Goss PE et al. Updated analysis of NCIC CTG MA.17 (letrozole vs placebo to letrozole vs placebo) post unblinding. San Antonio Breast Cancer Symposium 2005a;Abstract 16.

Goss PE et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005b;97(17):1262-71. Abstract

Joensuu H et al; FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354(8):809-20. Abstract

Perez EA et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. Proc ASCO 2007;Abstract 512.

Piccart-Gebhart MJ et al; HERA Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353(16):1659-72. Abstract

Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673-84. Abstract

Slamon D et al. BCIRG 006: 2^nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. San Antonio Breast Cancer Symposium 2006;Abstract 52.

Slamon D et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Presentation. San Antonio Breast Cancer Symposium 2005;Abstract 1.

Smith I et al; HERA Study Team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 2007;369(9555):29-36. Abstract

 

 

 

 

Table of Contents

Top of Page

Home · Search

Editor:
Neil Love, MD

Interviews

Melvin J Silverstein, MD
- Select publications

David M Hyams, MD
- Select publications

Charles E Geyer Jr, MD
- Select publications

Hope S Rugo, MD
- Select publications

Highlights of a CME Symposium Held in Conjunction with The American Society of Breast Surgeons Eighth Annual Meeting
- Select publications

A CME Audio Series and Activity

Faculty Disclosures

Editor's Office